Reich & Binstock
Free Initial Consultation
Toll Free: 877-643-3099
Local: 713-352-7883
877-643-3099 713-352-7883

November 2014 Archives

Risperdal adverse reactions updated

Ileus, or an intestinal blockage, has been added this spring to the list of numerous adverse reactions that have been voluntarily reported by patients taking the antipsychotic Risperdal (risperidone). The FDA approved Risperdal for the treatment of schizophrenia, acute manic or mixed episodes associated with Bipolar I, and irritability associated with autistic disorder.

NaturaLyte dialysis chemical recalled again

Fresenius Medical Care North America has recalled 58 lots of its 6.4-liter NaturaLyte Liquid Bicarbonate Concentrate used in dialysis. There were 49 lots in the April 10 recall and another nine in the May 1 expanded recall. The U.S. Food and Drug Administration, which issued its own safety communication on the Fresenius action, elevated the recall May 28 to its most serious level.

Risperdal lawsuits filed by youthful victims

The victims show it. And the juries will know it. Risperdal poses a risk to male children about which allegedly the manufacturer, Janssen Pharmaceuticals, either knew or should have known, and should have adequately warned. Instead the manufacturer marketed the drug to youth and unfortunate outcomes resulted across the nation.

FDA warns about lidocaine to treat teething pain

Based on its review of 22 reports of serious adverse reactions, including deaths, in 2014, the U.S. Food and Drug Administration is calling for a boxed warning on a prescription drug used to treat teething pain. The children in those reports ranged from 5-months-old to 2 and a half. At the same time, the agency is reiterating its rebuke of the use of over-the-counter topical solutions for the treatment of teething pain.

FDA panel discusses power morcellation risks, benefits

A panel of U.S. Food and Drug Administration experts, who met earlier this month near Washington, will report their findings in regard to the safety of laparoscopic power morcellation. The procedure, according to the FDA, can be used in "hysterectomy or myomectomy in women with uterine fibroids."

Compensation still attainable in transvaginal mesh lawsuits

Women who have been injured by the transvaginal mesh have been awarded settlements and have received favorable verdicts; nevertheless the opportunity to receive compensation will not last forever. The experienced attorneys at Reich & Binstock offer free consultations to women who used the transvaginal mesh and who suffered any number of serious injuries.

Federal Lipitor lawsuits pile up fast

If you were diagnosed with Type-2 diabetes after using the cholesterol-lowering drug Lipitor, there is a chance you are entitled to compensation for your diabetes injury. One way to find out whether there is a case for a Lipitor lawsuit is to get a free consultation from one of the experienced Lipitor attorneys at Reich & Binstock.

Lawsuits center on incretin diabetes drugs

On Aug. 15, 2013, there were 53 lawsuits pertaining to four diabetes drugs centralized at the U.S. District Court for the Southern District of California. As of July 15, 463 such lawsuits were pending before that very same court. Many were transferred there by the U.S. Judicial Panel on Multidistrict Litigation, which is the body that establishes multidistrict litigation courts to carry out pretrial management of multiple cases.

Pain a companion of transvaginal mesh victims

Women who were injured as a result of the use of the surgically implanted transvaginal mesh have shown a constellation of ailments. Included in the array, according to the U.S. Food and Drug Administration, are organ perforation and mesh erosion through the vagina. There are reports of infection and bleeding as well as urinary and neuro-muscular problems. All of this is very painful, and the road to relief often leads to surgery.

Risperdal side effect can be traumatic

The Journal of Clinical Psychopharmacology in April 2006 published an article that connected the dots between the use of the antipsychotic risperidone, the brand name of which is Risperdal, and a condition seen in adolescents known as gynecomastia or the development of female-like breasts in males.

Lipitor singled out itself in diabetes risk

Back in January, the U.S. Food and Drug Administration updated its safety advisories in regard to the anti-cholesterol drug Lipitor and other so-called "statin" drugs. It read, "People being treated with statins may have an increased risk of raised blood sugar levels and the development of Type 2 diabetes."

Laparoscopic power morcellation investigated

Lawsuits have been filed. Equipment has been withdrawn from the market. The U.S. Food and Drug Administration put out safety alerts. And, now, U.S. senators have called for a swift and stern regulatory response. All of these developments pertain to the use of the laparoscopic power morcellator.

Gynecomastia not the only Risperdal risk

A new study released Aug. 19 in the Annals of Internal Medicine showed that risperidone, the generic version of the antipsychotic Risperdal, and two other drugs in its class have been linked to a higher risk for acute kidney injury, or AKI, in older patients being treated for behavioral symptoms of dementia.

Lawsuits stem from testosterone replacement therapy

Three Texas plaintiffs and one Alabama defendant will find out in October from a panel of judges whether their federal testosterone replacement therapy lawsuits will be transferred to U.S. District Court for the Northern District of Illinois. Going on 200 federal cases are already there. Plaintiffs or their surviving next-of-kin claim testosterone replacement therapy led to serious injury, which proved fatal in some cases.

Contact Us

Contact Us For Legal Advice

Bold labels are required.

Contact Information

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.


Privacy Policy

4265 San Felipe
Suite 1000
Houston, TX 77027

Toll Free: 877-643-3099
Phone: 713-352-7883
Fax: 713-623-8724
Map & Directions